[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349571-105":59,"doc-detail-349571-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","nmr-metabolomics-and-glycomics-for-cancer-detection-in-patients-with-non-specific-symptoms-a-prospective-observational-cohort-study","NMR metabolomics and glycomics for cancer detection in patients with non-specific symptoms - A prospective observational cohort study","","Early cancer diagnosis in patients with non-specific symptoms is limited by insufficient discriminatory tests. Within the Oxfordshire Suspected CANcer (SCAN) pathway, serum 1H NMR-based metabolomics showed high-accuracy cancer identification. SCAN2 evaluates whether combining metabolomics with glycomics adds complementary molecular information and improves discrimination in a clinically complex, real-world population using NMR metabolomics and HPLC-MS glycomics with machine-learning classifiers.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nmr-metabolomics-and-glycomics-for-cancer-detection-in-patients-with-non-specific-symptoms-a-prospective-observational-cohort-study/349571/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nmr-metabolomics-and-glycomics-for-cancer-detection-in-patients-with-non-specific-symptoms-a-prospective-observational-cohort-study/349571.png","ImageObject",300,407,{"name":92,"@type":93},"mieayamfan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address?","Question",{"text":112,"@type":113},"The study addresses the limited availability of discriminatory tests for early cancer diagnosis in patients presenting with non-specific symptoms.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were metabolomics and glycomics measured and modeled?",{"text":117,"@type":113},"Serum from SCAN patients was analyzed using AXINON®-derived NMR metabolomics and HPLC-MS glycomics, and machine-learning models were trained and evaluated using ROC analysis with strict separation of training and test data.",{"name":119,"@type":110,"acceptedAnswer":120},"What performance improvements were reported after combining glycomics with metabolomics?",{"text":121,"@type":113},"In the full cohort, integration achieved AUC 0.814 (95% CI 0.808–0.820). After excluding major comorbidities and selected cancer types, performance improved to AUC 0.884 (95% CI 0.879–0.890).",{"name":123,"@type":110,"acceptedAnswer":124},"Why is the joint probability analysis used?",{"text":125,"@type":113},"Joint probability analysis incorporates an additional classifier for alternative non-cancer diagnoses and projects mean predicted probabilities into a two-dimensional space, providing an interpretable framework for cancer risk stratification across multimorbid pathways.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},349571,1790621614,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Articles  \nNMR metabolomics and glycomics for cancer detection inpatients with non-specific symptoms: a prospective observational cohort study  \nTereza Kacerova,a,b,c,∗∗,k Abi G. Yates,d,k James R. Larkin,d Boris Shulgin,d Jack J. J. J. Miller,e,f Philippa L. Harris Gleave,d Sebastian de Jel,g Jack Cheeseman,h Georgia Elgood-Hunt,h the SCAN Consortium,i,l Eric Schiffer,g Daniel I. R. Spencer,h Suzie Anthony,j and Daniel C. Anthonyd,∗  \naChemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, OX1 3TA, UK bKavli Institute of Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QU, UK cPhysical and Theoretical Chemistry, University of Oxford, Oxford, OX1 3QZ, UK  \ndDepartment of Pharmacology, University of Oxford, Oxford, OX1 3QT, UK  \neOxford Centre for Magnetic Resonance Research, University of Oxford, Oxford, OX3 9DU, UK fDepartment of Clinical Medicine, Aarhus University, Aarhus, 8200, Denmark  \ngnumares AG, Regensburg, 93053, Germany  \nhLudger Ltd, Culham Science Centre, Abingdon, OX14 3EB, UK  \niSCAN Consortium, Oxford University Hospitals NHS Foundation Trust and University of Oxford, Oxford, UK jInterventional Oncology, Department of Radiology, University of Oxford, Oxford, OX3 9DU, UK  \nSummary  \nBackground Early cancer diagnosis in patients with non-specific symptoms is limited by the lack of discriminatory tests. Within the Oxfordshire Suspected CANcer (SCAN) pathway, exploratory biomarker work showed that serum 1H NMR-based metabolomics can identify cancer with high accuracy. SCAN2 evaluated whether integrating metabolomics with glycomics provides complementary molecular information and improves discrimination in a clinically complex, real-world population.  \nMethods Serum from 369 SCAN patients (59 cancers) was analysed using AXINON® System-derived NMR metabolomics and HPLC-MS glycomics. Machine-learning models were trained to predict cancer status, with performance assessed by receiver operating characteristic (ROC) analysis of pooled cross-validated predictions. To place cancer risk in a broader clinical context, a second classifier modelling alternative non-cancer diagnosis was incorporated, and mean predicted probabilities from both models were jointly projected into a two-dimensional space, maintaining strict separation of training and test data.  \nFindings In the full cohort, integration of glycomics with metabolomics achieved an AUC of 0.814 (95% CI 0.808–0.820) . In a refined sub-cohort excluding major comorbidities and selected cancer types (32 cancers, 277 noncancers), performance improved to an AUC of 0.884 (95% CI 0.879–0.890) . Discriminatory features included cancer-associated biantennary fucosylated glycans alongside amino acid metabolites (glutamate, histidine) and lipoprotein-related measures. A classifier distinguishing metastatic from non-metastatic disease (n = 29 vs. 30) achieved an AUC of 0.80. Joint probability analysis in the full cohort preserved cancer-associated signatures across comorbidity burden, with projection-based classification achieving an accuracy of 89.2%(95% CI 85.7–92.6) .  \nInterpretation These findings validate the SCAN1 metabolomic signature in a more clinically complex cohort and indicate that integrating glycomics with metabolomics provides complementary biological information for cancer discrimination. Joint probability analysis provides an interpretable framework for cancer risk stratification within multimorbid diagnostic pathways, supporting the clinical potential of scalable multi-omics blood testing.  \nFunding EPSRC, EU Horizon 2020, Wellcome/MLSTF, Novo Nordisk Foundation.  \nCopyright © 2026 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)).  \nKeywords: Cancer detection; Multi-omics; Metabolomics; Glycomics; Non-specific symptoms  \n*Corresponding author.  \n**Corresponding author. C","cbCaijuty9EF0WQT","https://ap.wps.com/l/cbCaijuty9EF0WQT","pdf",6394177,22,"English","# Summary\n## Background\n## Methods\n## Findings\n## Interpretation\n# Research in context\n## Evidence before this study\n## Added value of this study","[{\"question\":\"What problem does the study address?\",\"answer\":\"The study addresses the limited availability of discriminatory tests for early cancer diagnosis in patients presenting with non-specific symptoms.\"},{\"question\":\"How were metabolomics and glycomics measured and modeled?\",\"answer\":\"Serum from SCAN patients was analyzed using AXINON®-derived NMR metabolomics and HPLC-MS glycomics, and machine-learning models were trained and evaluated using ROC analysis with strict separation of training and test data.\"},{\"question\":\"What performance improvements were reported after combining glycomics with metabolomics?\",\"answer\":\"In the full cohort, integration achieved AUC 0.814 (95% CI 0.808–0.820). After excluding major comorbidities and selected cancer types, performance improved to AUC 0.884 (95% CI 0.879–0.890).\"},{\"question\":\"Why is the joint probability analysis used?\",\"answer\":\"Joint probability analysis incorporates an additional classifier for alternative non-cancer diagnoses and projects mean predicted probabilities into a two-dimensional space, providing an interpretable framework for cancer risk stratification across multimorbid pathways.\"}]","NMR metabolomics and glycomics for cancer detection in patients with non-specific symptoms - A prospective observational cohort study | PDF",1790084347,55,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2690abea0566be0571e20a38304bfb44.webp",983,1310,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b5665833a864bef3e976d71c5bcc2bf.webp",982,1309,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8dd54465d2f531fa82132447f63086d4.webp",981,1308,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d8f548c78a388c67d4d787b9aff8287.webp",980,1306]